Recursion Pharmaceuticals Inc
NASDAQ:RXRX

Watchlist Manager
Recursion Pharmaceuticals Inc Logo
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Watchlist
Price: 6.545 USD 8.54%
Market Cap: 2.5B USD
Have any thoughts about
Recursion Pharmaceuticals Inc?
Write Note

Recursion Pharmaceuticals Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Recursion Pharmaceuticals Inc
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Total Current Liabilities
$93.2m
CAGR 3-Years
59%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%
No Stocks Found

Recursion Pharmaceuticals Inc
Glance View

Market Cap
2.5B USD
Industry
Biotechnology

In the bustling landscape of biotech innovation, Recursion Pharmaceuticals Inc. carves a distinctive niche by marrying the worlds of biology and advanced computational techniques. Founded in 2013, this Salt Lake City-based company embarked on a mission to decode the complex tapestry of disease biology through the lens of data science and machine learning. Recursion's approach centers around its unique platform that integrates automated experimental biology with artificial intelligence to map and navigate the intricate pathways of human cellular biology. By harnessing volumes of data from high-throughput biological experiments, they aim to unearth novel insights into a multitude of diseases, particularly those that have historically evaded effective therapeutic intervention. At the heart of Recursion's business model is its ability to discover potential drug candidates rapidly and efficiently, turning traditional pharmaceutical development on its head. The company generates revenue through strategic partnerships with pharmaceutical giants, leveraging its platform to accelerate drug discovery and development processes. Collaborations often involve sharing the risk and reward of drug discovery, with Recursion providing the technological backbone to sift through vast datasets and identify promising therapeutic compounds. Additionally, Recursion invests in its pipeline of proprietary drug candidates, targeting rare genetic diseases and areas of significant unmet medical need. By aligning cutting-edge technology with the complexities of human biology, Recursion Pharmaceuticals positions itself at the forefront of transforming how diseases are understood and how new treatments are developed.

RXRX Intrinsic Value
1.894 USD
Overvaluation 71%
Intrinsic Value
Price

See Also

What is Recursion Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
93.2m USD

Based on the financial report for Dec 31, 2023, Recursion Pharmaceuticals Inc's Total Current Liabilities amounts to 93.2m USD.

What is Recursion Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
59%

Over the last year, the Total Current Liabilities growth was -7%. The average annual Total Current Liabilities growth rates for Recursion Pharmaceuticals Inc have been 59% over the past three years .

Back to Top